We Can Medicines Co., Ltd.
We Can Medicines Co., Ltd. operates a chain of drug stores in Taiwan. The company offers medicine, health food, maternal and baby product, beauty care products, and medical equipment. It sells its products through retail stores and online under the VITALPLUS and Sapporo brands. The company was formerly known as Shenglin Pharmaceutical Co., Ltd. The company was founded in 1972 and is headquartered… Read more
Market Cap & Net Worth: We Can Medicines Co., Ltd. (6929)
We Can Medicines Co., Ltd. (TWO:6929) has a market capitalization of $8.85K (NT$292.70K) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #45132 globally and #2002 in its home market, demonstrating a -0.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying We Can Medicines Co., Ltd.'s stock price NT$31.65 by its total outstanding shares 9248 (9.25K).
We Can Medicines Co., Ltd. Market Cap History: 2025 to 2026
We Can Medicines Co., Ltd.'s market capitalization history from 2025 to 2026. Data shows growth from $9.62K to $8.85K (0.00% CAGR).
We Can Medicines Co., Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how We Can Medicines Co., Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6929 by Market Capitalization
Companies near We Can Medicines Co., Ltd. in the global market cap rankings as of March 18, 2026.
Key companies related to We Can Medicines Co., Ltd. by market ranking:
- Nestle SA (PINK:NSRGF): Ranked #55 globally with a market cap of $258.19 Billion USD.
- Nestlé S.A. (SW:NESN): Ranked #68 globally with a market cap of $226.90 Billion USD ( CHF207.77 Billion CHF).
- Danone S.A (OTCQX:GPDNF): Ranked #437 globally with a market cap of $49.73 Billion USD.
- Danone SA (PA:BN): Ranked #458 globally with a market cap of $47.46 Billion USD ( €46.23 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #55 | Nestle SA | PINK:NSRGF | $258.19 Billion | $100.43 |
| #68 | Nestlé S.A. | SW:NESN | $226.90 Billion | CHF80.84 |
| #437 | Danone S.A | OTCQX:GPDNF | $49.73 Billion | $78.67 |
| #458 | Danone SA | PA:BN | $47.46 Billion | €73.12 |
We Can Medicines Co., Ltd. Historical Marketcap From 2025 to 2026
Between 2025 and today, We Can Medicines Co., Ltd.'s market cap moved from $9.62K to $ 8.85K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$8.85K | -7.99% |
| 2025 | NT$9.62K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of We Can Medicines Co., Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.85K USD |
| MoneyControl | $8.85K USD |
| MarketWatch | $8.85K USD |
| marketcap.company | $8.85K USD |
| Reuters | $8.85K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.